Vanguard Group
XBIO icon

Vanguard Group’s Xenetic Biosciences XBIO Stock Holding History

Vanguard Group’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,698
Closed -$39.4K – 4571
2023
Q1 		$39.4K Sell
9,698
-6,164
-39% -$29.9K ﹤0.01% 4492
2022
Q4 		$45.2K Sell
15,862
-45,785
-74% -$202K ﹤0.01% 4455
2022
Q3 		$331K Hold
61,647
– – ﹤0.01% 4325
2022
Q2 		$494K Hold
61,647
– – ﹤0.01% 4299
2022
Q1 		$629K Hold
61,647
– – ﹤0.01% 4339
2021
Q4 		$795K Buy
61,647
+51,649
+517% +$824K ﹤0.01% 4327
2021
Q3 		$205K Buy
9,998
+926
+10% +$25.2K ﹤0.01% 4486
2021
Q2 		$185K Hold
9,072
– – ﹤0.01% 4375
2021
Q1 		$198K Buy
9,072
+5,101
+128% +$134K ﹤0.01% 4262
2020
Q4 		$81K Buy
+3,971
New +$48.1K ﹤0.01% 4156
2019
Q2 		– Sell
-388
Closed -$90K – 4186
2019
Q1 		$90K Buy
388
+2
+0.5% +$489 ﹤0.01% 4021
2018
Q4 		$75K Buy
386
+86
+29% +$26K ﹤0.01% 4033
2018
Q3 		$102K Buy
+300
New +$117K ﹤0.01% 4073

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NC
NewSquare Capital Newtown Square, Pennsylvania $1.15B AUM 24.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group's XBIO Position: Q2 2023 in Review

Vanguard Group sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 9,698 shares — an estimated $39.4K sold.

Vanguard Group first reported a position in XBIO in Q3 2018 and held it in 13 quarters. The position peaked at $795K in Q4 2021. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

  • Vanguard Group reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
  • Vanguard Group sold 9,698 Xenetic Biosciences shares in Q2 2023, an estimated $39.4K.
  • Vanguard Group first reported a position in Xenetic Biosciences in Q3 2018 and held it in 13 quarters.
  • Vanguard Group's Xenetic Biosciences position peaked at $795K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.